Allergy Therapeutics (AGY) — Financial Flexibility Index
Allergy Therapeutics (AGY) has a Financial Flexibility Index of -0.20x as of June 2025. Free cash flow of GBX-19.35 Million (operating CF GBX-21.09 Million minus capex GBX1.74 Million) represents 0% of total liabilities (GBX95.74 Million). Also explore Allergy Therapeutics (AGY) equity growth momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Allergy Therapeutics Financial Flexibility Index (2002–2025)
Historical Financial Flexibility Index trend for Allergy Therapeutics across 24 annual periods. Check AGY strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Allergy Therapeutics (2002–2025)
Year-by-year free cash flow to debt coverage for Allergy Therapeutics. For the full company profile including market capitalisation, see market cap of Allergy Therapeutics.
| Year | Flexibility Index | Free Cash Flow (GBX) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.27x | GBX-25.45 Million | GBX-28.72 Million | GBX95.74 Million | ▲ +43.5% |
| 2024 | -0.47x | GBX-28.74 Million | GBX-32.14 Million | GBX61.12 Million | ▼ -15.9% |
| 2023 | -0.41x | GBX-26.25 Million | GBX-30.92 Million | GBX64.70 Million | ▼ -29.1% |
| 2022 | -0.31x | GBX-11.05 Million | GBX-14.11 Million | GBX35.18 Million | ▼ -212.2% |
| 2021 | 0.28x | GBX11.08 Million | GBX8.52 Million | GBX39.55 Million | ▼ -19.8% |
| 2020 | 0.35x | GBX14.82 Million | GBX12.28 Million | GBX42.44 Million | ▲ +28.5% |
| 2019 | 0.27x | GBX8.41 Million | GBX5.60 Million | GBX30.94 Million | ▲ +523.3% |
| 2018 | -0.06x | GBX-1.80 Million | GBX-3.80 Million | GBX27.98 Million | ▼ -204.2% |
| 2017 | 0.06x | GBX1.68 Million | GBX178.00K | GBX27.22 Million | ▲ +115.3% |
| 2016 | -0.40x | GBX-10.61 Million | GBX-11.84 Million | GBX26.36 Million | ▼ -255.0% |
| 2015 | 0.26x | GBX4.21 Million | GBX3.12 Million | GBX16.23 Million | ▲ +12.6% |
| 2014 | 0.23x | GBX3.07 Million | GBX2.17 Million | GBX13.32 Million | ▲ +1.3% |
| 2013 | 0.23x | GBX3.25 Million | GBX2.43 Million | GBX14.29 Million | ▼ -27.7% |
| 2012 | 0.31x | GBX4.14 Million | GBX2.88 Million | GBX13.16 Million | ▲ +1234.3% |
| 2011 | -0.03x | GBX-790.00K | GBX-2.03 Million | GBX28.48 Million | ▼ -120.6% |
| 2010 | 0.13x | GBX3.40 Million | GBX1.70 Million | GBX25.23 Million | ▲ +376.1% |
| 2009 | 0.03x | GBX1.28 Million | GBX-440.00K | GBX45.25 Million | ▲ +105.8% |
| 2008 | -0.48x | GBX-16.70 Million | GBX-19.32 Million | GBX34.47 Million | ▲ +52.7% |
| 2007 | -1.02x | GBX-15.77 Million | GBX-18.88 Million | GBX15.40 Million | ▲ +10.3% |
| 2006 | -1.14x | GBX-5.91 Million | GBX-8.10 Million | GBX5.18 Million | ▼ -987.3% |
| 2005 | 0.13x | GBX846.00K | GBX-57.00K | GBX6.58 Million | ▼ -79.9% |
| 2004 | 0.64x | GBX2.67 Million | GBX1.91 Million | GBX4.16 Million | ▲ +43.6% |
| 2003 | 0.45x | GBX2.50 Million | GBX2.10 Million | GBX5.60 Million | ▲ +474.0% |
| 2002 | -0.12x | GBX-1.68 Million | GBX-2.01 Million | GBX14.07 Million | — |